<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 周一下跌了 8.2%。该公司交易最低价为 $42.19，最后交易价为 $41.39。在交易过程中，约有 9,467,116 股易手，较日均交易量 22,015,939 股下降了 57%。该股票此前收盘价为 $45.09。</p>
<p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>错过了 Hims &amp; Hers 的反弹？Clover Health 可能是下一个</li>
</ul>
<p>几家研究公司已对 HIMS 发布了报告。Truist Financial 将 Hims &amp; Hers Health 的目标价从 $24.00 上调至 $39.00，并在 2 月 26 日的研究报告中给予该公司 &#34;持有&#34; 评级。德意志银行将 Hims &amp; Hers Health 的目标价从 $23.00 上调至 $27.00，并在 11 月 6 日的研究报告中给予该股票 &#34;持有&#34; 评级。花旗集团将 Hims &amp; Hers Health 的目标价从 $25.00 上调至 $27.00，并在 2 月 25 日的研究报告中给予该公司 &#34;卖出&#34; 评级。Leerink Partners 将 Hims &amp; Hers Health 的目标价从 $24.00 上调至 $40.00，并在 2 月 25 日的报告中给予该股票 &#34;市场表现&#34; 评级。最后，美国银行将 Hims &amp; Hers Health 的目标价从 $18.00 上调至 $21.00，并在 2 月 20 日的报告中给予该公司 &#34;表现不佳&#34; 评级。两位投资分析师给予该股票 &#34;卖出&#34; 评级，七位给予 &#34;持有&#34; 评级，六位给予该公司 &#34;买入&#34; 评级。根据 MarketBeat 的数据，Hims &amp; Hers Health 目前的平均评级为 &#34;持有&#34;，共识目标价为 $37.23。</p>
<p><strong>阅读我们关于 Hims &amp; Hers Health 的最新报告</strong></p>
<h2>Hims &amp; Hers Health 股票表现</h2>
<ul>
<li>华尔街最受欢迎：当前 2 只高度被做空的股票</li>
</ul>
<p>该公司的 50 日简单移动平均线为 $36.57，200 日简单移动平均线为 $26.82。该公司的市值为 $90.3 亿，市盈率为 92.39，贝塔值为 1.35。</p>
<p>Hims &amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近一次发布财报是在 2 月 24 日，报告每股收益 (EPS) 为 $0.11，超出分析师共识预期的 $0.09，超出幅度为 $0.02。该公司在该季度的收入为 $4.8114 亿，而共识预期为 $4.9456 亿。Hims &amp; Hers Health 的净利润率为 8.19%，股本回报率为 10.97%。作为一个整体，卖方分析师预测 Hims &amp; Hers Health, Inc. 本年度将发布每股收益 0.29。</p>
<h2>内部买卖</h2>
<ul>
<li>MarketBeat 周回顾 – 02/17 - 02/21</li>
</ul>
<p>在其他新闻中，首席财务官 Oluyemi Okupe 于 1 月 13 日星期一出售了 11,581 股该股票，交易均价为 $24.44，总交易额为 $283,039.64。出售后，首席财务官现在直接持有该公司 118,077 股股票，价值 $2,885,801.88。这代表其持股减少了 8.93%。该交易已在与 SEC 的法律文件中披露，链接可通过此处获取。此外，内部人士 Michael Chi 于 2 月 24 日星期一出售了 17,303 股该股票，交易均价为 $48.14，总价值为 $832,966.42。交易后，内部人士现在持有该公司 193,601 股股票，价值约 $9,319,952.14。这代表其持股减少了 8.20%。该交易的披露信息可在此处找到。内部人士在过去九十天内共出售了 1,062,011 股公司股票，价值 $36,892,724。公司内部人士持有公司股票的 17.71%。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近买卖了该股票的股份。Crewe Advisors LLC 在第四季度购买了 Hims &amp; Hers Health 的新头寸，价值约 $28,000。Raleigh Capital Management Inc. 在第四季度将其在 Hims &amp; Hers Health 的持股增加了 1,100.0%。Raleigh Capital Management Inc. 现在拥有该公司 1,200 股股票，价值 $29,000，此前在上个季度购买了额外的 1,100 股。Blume Capital Management Inc. 在第四季度将其在 Hims &amp; Hers Health 的持股增加了 100.0%。Blume Capital Management Inc. 现在拥有该公司 1,200 股股票，价值 $29,000，此前在该期间购买了额外的 600 股。Smartleaf Asset Management LLC 在第四季度将其在 Hims &amp; Hers Health 的持股增加了 4,415.6%。Smartleaf Asset Management LLC 现在拥有该公司 1,445 股股票，价值 $36,000，此前在上个季度购买了额外的 1,413 股。最后，Summit Securities Group LLC 在第四季度购买了 Hims &amp; Hers Health 的新股份，价值 $38,000。对冲基金和其他机构投资者持有公司 63.52% 的股票。</p>
<h2>关于 Hims &amp; Hers Health</h2>
<p>(获取免费报告)</p>
<p>Hims &amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Hims &amp; Hers Health</li>
<li>每月分红股票的利弊</li>
<li>看跌投资者可以在抗衰退 ETF 中寻求避难所</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>3 只超卖的杰出七只股票处于关键水平：现在买入？</li>
<li>投资者如何识别并成功交易下跌股票</li>
<li>3M 到中期将达到 $175，且更高的高点很可能出现</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在你考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

<p>Hims & Hers Health（纽约证券交易所代码：HIMS）股票下跌 8.2%，至 41.39 美元，交易量较平均水平下降 57%。分析师的评级意见不一，其中两家为卖出，七家为持有，六家为买入。平均目标价为 37.23 美元。公司报告每股收益为 0.11 美元，超出预期，但营收为 4.8114 亿美元，未达到预期。内部人士的卖出行为引起关注，近期有大量股份被出售。对冲基金也表现活跃，上个季度报告了新头寸和增持股份</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) was down 8.2% on Monday . The company traded as low as $42.19 and last traded at $41.39. Approximately 9,467,116 shares changed hands during trading, a decline of 57% from the average daily volume of 22,015,939 shares. The stock had previously closed at $45.09.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 周一下跌了 8.2%。该公司交易最低价为 $42.19，最后交易价为 $41.39。在交易过程中，约有 9,467,116 股易手，较日均交易量 22,015,939 股下降了 57%。该股票此前收盘价为 $45.09。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Missed the Hims &amp; Hers Rally? Clover Health Could Be Next</li>
</ul>
<div class="lb-trans"><ul>
<li>错过了 Hims &amp; Hers 的反弹？Clover Health 可能是下一个</li>
</ul>
</div><p>Several research firms have issued reports on HIMS. Truist Financial lifted their target price on Hims &amp; Hers Health from $24.00 to $39.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, February 26th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims &amp; Hers Health from $23.00 to $27.00 and gave the stock a &#34;hold&#34; rating in a research report on Wednesday, November 6th. Citigroup increased their target price on shares of Hims &amp; Hers Health from $25.00 to $27.00 and gave the company a &#34;sell&#34; rating in a research report on Tuesday, February 25th. Leerink Partners lifted their price target on shares of Hims &amp; Hers Health from $24.00 to $40.00 and gave the stock a &#34;market perform&#34; rating in a report on Tuesday, February 25th. Finally, Bank of America increased their price objective on Hims &amp; Hers Health from $18.00 to $21.00 and gave the company an &#34;underperform&#34; rating in a report on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Hims &amp; Hers Health presently has an average rating of &#34;Hold&#34; and a consensus price target of $37.23.</p>
<div class="lb-trans"><p>几家研究公司已对 HIMS 发布了报告。Truist Financial 将 Hims &amp; Hers Health 的目标价从 $24.00 上调至 $39.00，并在 2 月 26 日的研究报告中给予该公司 &#34;持有&#34; 评级。德意志银行将 Hims &amp; Hers Health 的目标价从 $23.00 上调至 $27.00，并在 11 月 6 日的研究报告中给予该股票 &#34;持有&#34; 评级。花旗集团将 Hims &amp; Hers Health 的目标价从 $25.00 上调至 $27.00，并在 2 月 25 日的研究报告中给予该公司 &#34;卖出&#34; 评级。Leerink Partners 将 Hims &amp; Hers Health 的目标价从 $24.00 上调至 $40.00，并在 2 月 25 日的报告中给予该股票 &#34;市场表现&#34; 评级。最后，美国银行将 Hims &amp; Hers Health 的目标价从 $18.00 上调至 $21.00，并在 2 月 20 日的报告中给予该公司 &#34;表现不佳&#34; 评级。两位投资分析师给予该股票 &#34;卖出&#34; 评级，七位给予 &#34;持有&#34; 评级，六位给予该公司 &#34;买入&#34; 评级。根据 MarketBeat 的数据，Hims &amp; Hers Health 目前的平均评级为 &#34;持有&#34;，共识目标价为 $37.23。</p>
</div><p><strong>Read Our Latest Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Hims &amp; Hers Health 的最新报告</strong></p>
</div><h2>Hims &amp; Hers Health Stock Performance</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 股票表现</h2>
</div><ul>
<li>Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>华尔街最受欢迎：当前 2 只高度被做空的股票</li>
</ul>
</div><p>The firm's 50 day simple moving average is $36.57 and its 200 day simple moving average is $26.82. The firm has a market capitalization of $9.03 billion, a price-to-earnings ratio of 92.39 and a beta of 1.35.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 $36.57，200 日简单移动平均线为 $26.82。该公司的市值为 $90.3 亿，市盈率为 92.39，贝塔值为 1.35。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, sell-side analysts forecast that Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近一次发布财报是在 2 月 24 日，报告每股收益 (EPS) 为 $0.11，超出分析师共识预期的 $0.09，超出幅度为 $0.02。该公司在该季度的收入为 $4.8114 亿，而共识预期为 $4.9456 亿。Hims &amp; Hers Health 的净利润率为 8.19%，股本回报率为 10.97%。作为一个整体，卖方分析师预测 Hims &amp; Hers Health, Inc. 本年度将发布每股收益 0.29。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>MarketBeat Week in Review – 02/17 - 02/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/17 - 02/21</li>
</ul>
</div><p>In other news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $24.44, for a total transaction of $283,039.64. Following the sale, the chief financial officer now directly owns 118,077 shares of the company's stock, valued at $2,885,801.88. This represents a 8.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $48.14, for a total value of $832,966.42. Following the transaction, the insider now owns 193,601 shares of the company's stock, valued at approximately $9,319,952.14. This represents a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,062,011 shares of company stock valued at $36,892,724 over the last ninety days. Company insiders own 17.71% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Oluyemi Okupe 于 1 月 13 日星期一出售了 11,581 股该股票，交易均价为 $24.44，总交易额为 $283,039.64。出售后，首席财务官现在直接持有该公司 118,077 股股票，价值 $2,885,801.88。这代表其持股减少了 8.93%。该交易已在与 SEC 的法律文件中披露，链接可通过此处获取。此外，内部人士 Michael Chi 于 2 月 24 日星期一出售了 17,303 股该股票，交易均价为 $48.14，总价值为 $832,966.42。交易后，内部人士现在持有该公司 193,601 股股票，价值约 $9,319,952.14。这代表其持股减少了 8.20%。该交易的披露信息可在此处找到。内部人士在过去九十天内共出售了 1,062,011 股公司股票，价值 $36,892,724。公司内部人士持有公司股票的 17.71%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently bought and sold shares of the stock. Crewe Advisors LLC purchased a new position in shares of Hims &amp; Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. lifted its stake in Hims &amp; Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its position in shares of Hims &amp; Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Hims &amp; Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims &amp; Hers Health in the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近买卖了该股票的股份。Crewe Advisors LLC 在第四季度购买了 Hims &amp; Hers Health 的新头寸，价值约 $28,000。Raleigh Capital Management Inc. 在第四季度将其在 Hims &amp; Hers Health 的持股增加了 1,100.0%。Raleigh Capital Management Inc. 现在拥有该公司 1,200 股股票，价值 $29,000，此前在上个季度购买了额外的 1,100 股。Blume Capital Management Inc. 在第四季度将其在 Hims &amp; Hers Health 的持股增加了 100.0%。Blume Capital Management Inc. 现在拥有该公司 1,200 股股票，价值 $29,000，此前在该期间购买了额外的 600 股。Smartleaf Asset Management LLC 在第四季度将其在 Hims &amp; Hers Health 的持股增加了 4,415.6%。Smartleaf Asset Management LLC 现在拥有该公司 1,445 股股票，价值 $36,000，此前在上个季度购买了额外的 1,413 股。最后，Summit Securities Group LLC 在第四季度购买了 Hims &amp; Hers Health 的新股份，价值 $38,000。对冲基金和其他机构投资者持有公司 63.52% 的股票。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Hims &amp; Hers Health</li>
<li>每月分红股票的利弊</li>
<li>看跌投资者可以在抗衰退 ETF 中寻求避难所</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>3 只超卖的杰出七只股票处于关键水平：现在买入？</li>
<li>投资者如何识别并成功交易下跌股票</li>
<li>3M 到中期将达到 $175，且更高的高点很可能出现</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hims & Hers Health (NYSE:HIMS) 股价下跌 8.2% - 你应该卖出吗？